NeOnc discusses NEO100-01 Phase 2a results; no data in filing excerpt

NEONC TECHNOLOGIES HOLDINGS, INC.

Hosted investor call on Aug 12, 2026 to discuss Phase 2a top-line results of NEO100-01 in recurrent IDH1 mutant high-grade glioma.
Participants included CEO Amir Heshmatpour, CFO Keithly Garnett, CSO Thomas Chen, and Chief Clinical Officer Josh Neman.
Provided transcript does not include specific efficacy or safety data; only call introduction is in the exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.